FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2893213316> ?p ?o ?g. }

• W2893213316 endingPage "118" @default.
• W2893213316 startingPage "111" @default.
• W2893213316 abstract "Cytarabine (Ara-C) has become cornerstones for the treatment of hatmatological malignancies for several decades; however, it still faces serious challenges in clinical applications due to its side effects such as hand foot syndrome (HFS) and stomatitis. Therefore, considerable researchers have devoted to looking for the new derivative with desirable activity and low toxicity. A new prodrug based on the conjugation of cytarabine with lauric acid (LA-Ara) was synthesized in our group, and it could self-assemble into nanofibers (NFs) in aqueous solution with high drug loading (57 wt%). The lauric acid moiety protects NH2 group of from the enzymatic attachment and simultaneously raises the lipophilicity of Ara-C, thus obviously prolongs its plasma half-life. The oil/water partition coefficient (lg P) and the permeability of cell membrane of LA-Ara were obviously increased compared with Ara-C. Furthermore, the in vitro gastrointestinal stability results indicated the prodrug was suitable to be administrated orally. In the current study, the in vitro cytotoxicity and in vivo anti breast cancer experimental results indicate LA-Ara markedly improved antitumor activity compared with free Ara-C. The favorable safety evaluations elucidated its potentiality for oral alternative treatment to Ara-C. Importantly, LA-Ara can effectively decrease the incidence of toxic effects (HFS and stomatitis) of Ara-C, thereby exhibiting favorable skin safety profile. Overall, these results indicated the LA-Ara would be an excellent candidate for further clinical investigation and simultaneously highlight the prospects of Ara-C prodrug strategies in solid tumors therapy." @default.
• W2893213316 created "2018-10-05" @default.
• W2893213316 creator A5000724192 @default.
• W2893213316 creator A5003927896 @default.
• W2893213316 creator A5005532555 @default.
• W2893213316 creator A5024053527 @default.
• W2893213316 creator A5043148975 @default.
• W2893213316 creator A5066589676 @default.
• W2893213316 creator A5079998635 @default.
• W2893213316 date "2018-12-01" @default.
• W2893213316 modified "2023-09-25" @default.
• W2893213316 title "A preclinical evaluation of cytarabine prodrug nanofibers assembled from cytarabine-lauric acid conjugate toward solid tumors" @default.
• W2893213316 cites W1576183422 @default.
• W2893213316 cites W1808968650 @default.
• W2893213316 cites W1968865933 @default.
• W2893213316 cites W1982297030 @default.
• W2893213316 cites W1988072378 @default.
• W2893213316 cites W2012911400 @default.
• W2893213316 cites W2032870044 @default.
• W2893213316 cites W2038418998 @default.
• W2893213316 cites W2048250529 @default.
• W2893213316 cites W2049281292 @default.
• W2893213316 cites W2054143933 @default.
• W2893213316 cites W2057561223 @default.
• W2893213316 cites W2085016383 @default.
• W2893213316 cites W2108843890 @default.
• W2893213316 cites W2119027011 @default.
• W2893213316 cites W2133696161 @default.
• W2893213316 cites W2147458973 @default.
• W2893213316 cites W2149436766 @default.
• W2893213316 cites W2159746057 @default.
• W2893213316 cites W2166741490 @default.
• W2893213316 cites W2186393855 @default.
• W2893213316 cites W2280955151 @default.
• W2893213316 cites W2309627571 @default.
• W2893213316 cites W2326492319 @default.
• W2893213316 cites W2503470809 @default.
• W2893213316 cites W2520630506 @default.
• W2893213316 cites W2523237690 @default.
• W2893213316 cites W2537869344 @default.
• W2893213316 cites W2550415085 @default.
• W2893213316 cites W2612295103 @default.
• W2893213316 cites W2621055690 @default.
• W2893213316 cites W2624556462 @default.
• W2893213316 cites W2734381642 @default.
• W2893213316 cites W2747169234 @default.
• W2893213316 cites W2753581915 @default.
• W2893213316 cites W2762785181 @default.
• W2893213316 cites W2763159879 @default.
• W2893213316 cites W2766218146 @default.
• W2893213316 cites W2766500377 @default.
• W2893213316 cites W2783495750 @default.
• W2893213316 cites W2784550998 @default.
• W2893213316 doi "https://doi.org/10.1016/j.ijpharm.2018.09.043" @default.
• W2893213316 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30268848" @default.
• W2893213316 hasPublicationYear "2018" @default.
• W2893213316 type Work @default.
• W2893213316 sameAs 2893213316 @default.
• W2893213316 citedByCount "11" @default.
• W2893213316 countsByYear W28932133162020 @default.
• W2893213316 countsByYear W28932133162021 @default.
• W2893213316 countsByYear W28932133162022 @default.
• W2893213316 countsByYear W28932133162023 @default.
• W2893213316 crossrefType "journal-article" @default.
• W2893213316 hasAuthorship W2893213316A5000724192 @default.
• W2893213316 hasAuthorship W2893213316A5003927896 @default.
• W2893213316 hasAuthorship W2893213316A5005532555 @default.
• W2893213316 hasAuthorship W2893213316A5024053527 @default.
• W2893213316 hasAuthorship W2893213316A5043148975 @default.
• W2893213316 hasAuthorship W2893213316A5066589676 @default.
• W2893213316 hasAuthorship W2893213316A5079998635 @default.
• W2893213316 hasConcept C108215921 @default.
• W2893213316 hasConcept C126322002 @default.
• W2893213316 hasConcept C150903083 @default.
• W2893213316 hasConcept C185592680 @default.
• W2893213316 hasConcept C207001950 @default.
• W2893213316 hasConcept C2776694085 @default.
• W2893213316 hasConcept C2778041864 @default.
• W2893213316 hasConcept C2781003072 @default.
• W2893213316 hasConcept C543025807 @default.
• W2893213316 hasConcept C55493867 @default.
• W2893213316 hasConcept C71924100 @default.
• W2893213316 hasConcept C86803240 @default.
• W2893213316 hasConcept C98274493 @default.
• W2893213316 hasConceptScore W2893213316C108215921 @default.
• W2893213316 hasConceptScore W2893213316C126322002 @default.
• W2893213316 hasConceptScore W2893213316C150903083 @default.
• W2893213316 hasConceptScore W2893213316C185592680 @default.
• W2893213316 hasConceptScore W2893213316C207001950 @default.
• W2893213316 hasConceptScore W2893213316C2776694085 @default.
• W2893213316 hasConceptScore W2893213316C2778041864 @default.
• W2893213316 hasConceptScore W2893213316C2781003072 @default.
• W2893213316 hasConceptScore W2893213316C543025807 @default.
• W2893213316 hasConceptScore W2893213316C55493867 @default.
• W2893213316 hasConceptScore W2893213316C71924100 @default.
• W2893213316 hasConceptScore W2893213316C86803240 @default.
• W2893213316 hasConceptScore W2893213316C98274493 @default.
• W2893213316 hasFunder F4320321001 @default.

• next